Exposure to New Emerging Bisphenols Among Young Children in Switzerland

Fiorella Lucarini1, Tropoja Krasniqi1, Gaëlle Bailat Rosset2

  • 1Department of Biomedical Sciences, University of Lausanne, 1011 Lausanne, Switzerland.

Insights

Young children in Switzerland are exposed to bisphenol analogues, including bisphenol C (BPC) and bisphenol M (BPM). Urinary levels of bisphenol S (BPS) and bisphenol F (BPF) exceeded those of bisphenol A (BPA).

Area of Science:

  • Environmental Health
  • Toxicology
  • Pediatric Health

Background:

  • Restrictions on bisphenol A (BPA) have led to increased use of analogues.
  • Exposure to these emerging bisphenol analogues in young children is not well understood.
  • Urinary biomonitoring is crucial for assessing chemical exposure in vulnerable populations.

Purpose of the Study:

  • To characterize infant and toddler exposure to BPA and 14 bisphenol analogues.
  • To establish a baseline for bisphenol exposure in Swiss children.
  • To inform public health strategies for exposure reduction.

Main Methods:

  • Non-invasive collection of infant and toddler urine samples from diapers (n=109) in Swiss daycare centers.
  • Analysis of urinary concentrations of BPA and 14 emerging bisphenol analogues.
  • Statistical analysis to identify correlations between bisphenol levels and demographic factors.

Main Results:

  • Bisphenols were detected in 47% of samples.
  • Bisphenol C (BPC) and bisphenol M (BPM) were the most frequently detected analogues.
  • Mean urinary concentrations of bisphenol S (BPS) and bisphenol F (BPF) were higher than BPA.
  • A negative correlation was found between BPM concentration and age.

Conclusions:

  • This study provides the first characterization of bisphenol exposure in Swiss infants and toddlers.
  • BPS and BPF are significant urinary bisphenol metabolites in this population.
  • Findings support the need for biomonitoring and targeted exposure reduction strategies for young children.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.8K
Types of Toxins01:36

Types of Toxins

Humans continually engage with an environment rich in potentially harmful chemicals. These are introduced to our bodies through inhalation, ingestion, or skin contact. These chemicals exist in various forms, such as air and environmental pollutants, agricultural chemicals, organic solvents, and heavy metals.
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...
3.0K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
149
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
115